Symbols

LGND

Ligand·NASDAQ

--(--)

LGND fundamentals

LGND Q4 2025 Earnings

Ligand (LGND) released its earnings on Feb 26, 2026: revenue was 59.67M (YoY +39.37%), beat estimates; EPS was 2.02 (YoY +59.06%), beat estimates.

Revenue / YoY

59.67M

+39.37%

EPS / YoY

2.02

+59.06%

Report date

Feb 26, 2026

LGND Earnings Call Summary for Q4,2025

Exceptional 2025 Performance: Adjusted EPS up 42% to $8.13, royalty revenue +48%. 2026 guidance: EPS $8-$9M, royalty $200-$225M.
High-Growth Pipeline: 23% CAGR 2026-2030, driven by FILSPARI, Ohtuvayre, and 5+ late-stage assets.
Strategic Capital Deployment: $1B+ to invest in high-impact royalty streams, including QTORIN ($100M-$300M peak) and lasofoxifene ($80M+).
Portfolio Management: Proactive engagement with 5-10 assets, e.g., LeonaBio partnership for Phase 3 breast cancer drug.
Market Leadership: Leading in biopharma royalty financing with $1B+ deployable capital, doubling market share in 5 years.

Earnings

EPS

Revenue

Revenue & Expenses

LGND has released its 2025 Q4 earnings report, with revenue of 59.67M, reflecting a YoY change of 39.37%, and net profit of 44.78M, showing a YoY change of 244.06%. The Sankey diagram below clearly presents LGND's revenue sources and cost distribution.

Key Indicators

Ligand (LGND) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Ligand (LGND)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Ligand (LGND)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Ligand (LGND)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown